Evogene Ltd. · NASDAQ:EVGN
Evogene — Investor Presentation (May 2022)
41 slides from Evogene's investor presentation, May 26, 2022
Slide 1: Investor Presentation
INVESTOR PRESENTATION Ofer Haviv, President & CEO March 2022
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or
Slide 3: Agenda
Agenda Introduction Fields of activity Main subsidiaries Summary Annex I - Technology Annex II - Financial Fundamentals 3
Slide 4: Our Vision: Decoding Biology
OUR VISION DECODING BIOLOGY Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies. 4
Slide 5: Life-science product development
Life-science product development Low probability of success with high cost and long time-to-market Pharmaceutical Ag-chemicals Industry Industry Cost of developing a single Time to develop a new pharmaceutical drug crop protection product In the 1970’s 1995 2000 2005-8 2010-15 $180 million Number of
Slide 6: The ultimate case of a needle in the haystack
Life-science product development The ultimate case of a needle in the haystack Discovery Optimization Development Regulation Agriculture Approved Product Product Candidates Pharma The challenge: Finding the winning candidates out of a vast number of possible prospects, that address a complex myriad
Slide 7: The opportunity
HUMAN HEALTH The opportunity Utilizing an advanced computational biology platform, to identify the most promising candidates addressing multiple development challenges, towards successful life-science products: • Increase probability of success AGRICULTURE • Reducing time and cost OTHER INDUSTRIES 7
Slide 8: When biology meets disruptive technologies platform
When biology meets disruptive technologies platform Incorporating deep scientific understandings BIOLOGY together with big data and advanced artificial intelligence technologies (AI), to successfully BIG DATA AI discover & guide the development of novel life-science based products. – Computational P
Slide 9: Tailor-made Engines for product discovery & development
Tailor-made Engines for product discovery & MICROBES development The CPB platform enhances product discovery and development through dedicated Engines for products based on SMALL MOLECULES three core components: ▪ Microbes ▪ Small molecules ▪ Genetic elements GENETIC ELEMENTS 9
Slide 10: Developing an eco-system around our tech engines
Case Study – Potential uses for MicroBoost AI Microbials Therapeutic for Crops microbials Food Probiotics Developing an Human & eco-system around our tech engines Animal Probiotics Dietary Supplements Wastewater Plastic Treatments Degradation Chemicals Oil Spill Clearing Source for Enzymes 10
Slide 11: User Interface
Sa. Micro “2/300St"" User Interface 6,650,502 46,237 200,599,577 YQ 93,995 evOgene DECODING BIOL
Slide 12: Business Model: Product-oriented subsidiaries
1 Business Model Product-oriented subsidiaries powered by Evogene’s technology Establish independent entities focusing on a defined commercial field with an exclusive license to use Evogene’s unique solutions for product development. Subsidiaries: Ag-chemicals Microbiome based therapeutics Medical c
Slide 13: Business Model: Collaborations
2 Collaborations powered by Business Model Evogene’s technology for the development of innovative products Joint development with leading companies for defined products utilizing Evogene’s unique solution. Typically, partner leads later-stage development and product commercialization. Collaborations
Slide 14: Agenda
Agenda Introduction Fields of activity Main subsidiaries Summary Annex I - Technology Annex II - Financial Fundamentals 14
Slide 15: Current life-science based products powered by Evogene's tech-engines
Current life-science based products powered by Evogene’s tech-engines OTHER HUMAN HEALTH AGRICULTURE INDUSTRIES Microbiome MICROBES based Ag-Biologicals Therapeutics SMALL MOLECULES Drugs based on Ag-Chemicals small molecules GENETIC ELEMENTS Ag-solutions Medical Seed Traits for castor Cannabis oil
Slide 16: Development & commercialization through subsidiaries and collaborations
Development & commercialization through subsidiaries and collaborations HUMAN HEALTH AGRICULTURE OTHER INDUSTRIES MICROBES SMALL MOLECULES * GENETIC ELEMENTS Seed Traits [division] * Non-exclusive license 16
Slide 17: Evogene Group
Evogene Group Human Other Health Agriculture Industries 93%* 100%* 98%* 70%* (28% Corteva) Internal division of Evogene 100%* Microbiome based Medical Cannabis Ag Chemicals Ag Biologicals Seed Traits Castor Oil Therapeutics Production • Immuno-oncology • High yield & consumer • Herbicides • Bio-Stim
Slide 18: Main Subsidiaries: Industry Landscape
Main Subsidiaries: Industry Landscape Microbiome Based Therapeutics Medical Cannabis Ag-Biologicals Ag-Chemicals Market Cap/Funds Market Cap/Funds Market Cap/Funds Market Cap/Funds Company Name Company Name Company Name Company Name Raised Raised Raised Raised $166m* $1.6B* Raised $116m# Raised $24m
Slide 19: Agenda
Agenda Introduction Fields of activity Main subsidiaries Summary Annex I - Technology Annex II - Financial Fundamentals 19
Slide 20: Human Microbiome: Mission, Product Pipeline, Value Drivers
| Human Microbiome Powered by Mission: Discovery and development of novel therapies for microbiome-related human disorders using computational biology Product Pipeline: Expected main near-term value drivers: Immuno-oncology program: • Combination therapy for cancer with checkpoint inhibitors • Pre-c
Slide 21: Example Results: Human Microbiome
| Human Microbiome Example Results: Immuno-Oncology program – BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone 21
Slide 22: Medical Cannabis: Mission, Product Pipeline, Value Drivers
| Medical Cannabis Powered by Mission: Commercialize effective, precise and stable medical cannabis products, based on decoding plant genetics, for optimized therapeutic effect Product Pipeline: Expected main near-term value drivers: MetaYield+ Products: 2022 ▪ MetaYield+ - commercial launch and sal
Slide 23: Medical Cannabis: First Products
| Medical Cannabis First Products: MetaYield products– increased compounds per area, addressing the T20/C4 (17%-24% THC & 1%-7% CBD) and T15/C3 (11%-19% THC & 0.5%-5.5% CBD) market segments. Medical Cannabis aiming at high THC, high yield, big inflorescence and dense trichomes 23
Slide 24: Ag-Chemicals: Mission, Product Pipeline, Value Drivers
| Ag-Chemicals Powered by Mission: Design next-generation, effective and sustainable crop protection products by leveraging predictive biology & chemistry Product Pipeline: Expected main near-term value drivers: Herbicides: 2022 • Novel MoA (Mode-of-Action) selective/non-selective ▪ New MoA Herbicid
Slide 25: Example Results: Ag-Chemicals
| Ag-Chemicals Example Results: New MoA Herbicide - APH1 (weed) Field test of APH1 against a panel of grass and broadleaf weeds – untreated control vs APH1 Greenhouse testing of APH1 – modified tobacco plants with resistance trait vs unmodified control 25
Slide 26: Ag-Biologicals: Mission, Product Pipeline, Value Drivers
| Ag-Biologicals Powered by Mission: Improve food quality, sustainability and agriculture productivity through microbiome based ag-biologicals technology and products Product Pipeline: Expected main near-term value drivers: Bio-stimulants (yield enhancement): ▪ Bio-stimulants 1– focus on wheat and a
Slide 27: Example Results: Ag-Biologicals
| Ag-Biologicals Example Results: - result™ inoculant (bio-stimulant) - LAV 311 & LAV 312 leading bio-fungicide candidates for fruit rot Lavie Bio’s wheat field in the USA during harvest – initial sales in 2022 Example of treatment against Botrytis Cinerea in vines – untreated control vs treated vin
Slide 28: Subsidiaries Expected main near-term value drivers
Subsidiaries Expected main near-term value drivers 2022 2023 IBD – initiate scale-up for Immuno-oncology – readout IBD – clinical batch production Immuno-oncology – pre-IND GMP production of drug from proof-of-concept, first in of drug candidate for IBD as meeting with FDA candidate for IBD human st
Slide 29: Agenda
Agenda Introduction Fields of activity Main subsidiaries Summary Annex I - Technology Annex II - Financial Fundamentals 29
Slide 30: Employees
140 Employees Computational chemistry Bioinformatics 30 Microbiology % Biochemistry PhDs 56 % Women Incl. chairperson of the board 30
Slide 31: Summary
Summary Our vision - Revolutionizing life-science based product Dual based business model - utilizing Evogene’s solutions for: discovery & development, utilizing cutting edge computational 1. Product development & commercialization through subsidiaries biology technologies. 2. Product development &
Slide 32: Thank You!
+ THANK YOU! evOgene ECODING BIOLOGY ~
Slide 33: Annex I: Technology
Annex I: Technology evOgene DECODING BIOLOGY -*K 33
Slide 34: The challenge in creating life-science based products
The challenge in creating life-science based products Discovery Development Product Candidate Efficacy Safety Selectivity Shelf-life Other Product Definition Selection Launch 34
Slide 35: The challenge in creating life-science based products
The challenge in creating life-science based products Common practice Discovery – selection of product candidates mainly addressing efficacy Product Candidate Efficacy Safety Selectivity Shelf-life Other Product Definition Selection Launch 35
Slide 36: The challenge in creating life-science based products
The challenge in creating life-science based products Common practice Discovery – selection of product candidates mainly addressing efficacy Development – inefficient optimization & difficulty in addressing a single challenge without impairing others Low probability of success Long time to market Hi
Slide 37: Evogene's AI-based solution: Discovery
Evogene’s AI-based solution: Discovery A multi-attribute computational selection of product candidates, addressing relevant challenges using dedicated training data sets and AI. Product Candidate Efficacy Safety Selectivity Shelf-life Other Product Definition Selection Launch 37
Slide 38: Evogene's AI-based solution: Development
Evogene’s AI-based solution: Development A multi-attribute computational analysis, addressing a specific development challenge of the selected candidate, without impairing its ability to address other product attributes. Product Candidate Efficacy Safety Selectivity Shelf-life Other Product Definiti
Slide 39: Evogene's AI engines provide tailor-made solutions
Evogene’s AI engines provide tailor-made solutions Discovery Computational prediction of candidates, to serve as the product’s core-component, addressing multiple key product attributes. Development Computational driven solution for guiding and assessing the optimization process of the selected core
Slide 40: Annex II: Financial Fundamentals
Annex II: Financial Fundamentals 40
Slide 41: Key Financials: Balance Sheet
Key Financials: Thousands of US $ 31.12.2021 31.12.2020 Balance Sheet Current Assets 56,890 51,823 Long-Term Assets 19,414 20,092 Total Assets 76,304 71,915 Current Liabilities 6,882 9,676 Key Points: • Consolidated cash position: ~$54 million as of Long-Term Liabilities 6,002 5,357 31.12.2021, of w